Valganciclovir is an oral antiviral medicine used to treat and prevent infections caused by cytomegalovirus (CMV), a virus that can seriously affect the eyes and other organs in people with weakened immune systems. It belongs to a class of medicines called antiviral agents and is the oral prodrug of intravenous ganciclovir. It is a prescription-only medicine.

Therapeutic Class: Antiviral medicine for cytomegalovirus (CMV) infection.

Pharmacological Class: Nucleoside analog, prodrug of ganciclovir; CMV DNA polymerase inhibitor.

Drug Family: Guanosine nucleoside analogs.

ATC Classification: J05AB14 (Valganciclovir).

• Approved: Treatment of cytomegalovirus (CMV) retinitis in adults with AIDS, and prevention of CMV disease in adult and pediatric kidney, heart, and kidney-pancreas transplant patients at high risk.

• Commonly used for: Immunocompromised patients — those with advanced HIV/AIDS or organ transplant recipients — who are at risk of or diagnosed with CMV-related disease.

• Off-label use (only under medical guidance): Sometimes used to manage Epstein-Barr virus (EBV)-related conditions or in other transplant settings under specialist guidance; not a routine approved use.

●       Oral tablets: 450 mg.

●       Oral solution: for patients who cannot swallow tablets, particularly children, dosed by body surface area.

Valganciclovir is inactive on its own and is converted in the body into ganciclovir, its active form. Ganciclovir then blocks an enzyme the CMV virus needs (CMV DNA polymerase) to copy its genetic material, stopping the virus from multiplying and helping control the infection.

• Standard dose (CMV retinitis, induction): 900 mg (two 450 mg tablets) taken with food twice daily for 21 days.

• Condition-wise dose (maintenance/prevention): 900 mg once daily following induction, or as prophylaxis in high-risk transplant patients; dose reduced in renal impairment (e.g., 450 mg twice weekly in significant impairment).

• Route: Oral, taken with food to improve absorption.

• Missed dose: Take as soon as remembered unless close to the next dose; don't double up.

• Overdose: Can cause severe bone marrow suppression or kidney impairment; needs urgent medical attention.

• Common: Diarrhoea, nausea, headache, and low blood counts (particularly neutropenia).

• Serious: Significant bone marrow suppression (severe neutropenia, anaemia, low platelets), kidney function changes, and central nervous system effects (seizures, confusion, dizziness).

• Emergency symptoms: Signs of serious infection (fever, chills) linked to low white cell counts, unusual bleeding or bruising, seizures, or severe confusion.

• Recovery advice: Regular blood count monitoring allows early detection of bone marrow suppression, often the main reason for dose adjustment; adequate hydration supports kidney function during treatment.

• Pregnancy: Not recommended; may cause fetal harm based on animal data.

• Breastfeeding: Not recommended during treatment.

• Liver disease: No specific dose adjustment established; used with routine monitoring.

• Kidney disease: Requires dose reduction based on creatinine clearance; closely monitored.

• Elderly: Used with caution, particularly given the likelihood of reduced kidney function in this age group.

• Children: Approved for prevention of CMV disease in pediatric kidney and heart transplant patients at high risk, with weight/body-surface-area-based dosing.

●       Other bone marrow suppressing drugs (e.g., zidovudine, certain chemotherapy agents): combined use increases the risk of severe blood count drops.

●       Imipenem-cilastatin: combining with valganciclovir/ganciclovir has been associated with seizures; used with caution.

●       Probenecid: can reduce elimination of ganciclovir, raising its levels.

●       Mycophenolate mofetil (used in transplant patients): may compete with valganciclovir for elimination, potentially raising levels of both.

●       Complete blood counts (particularly neutrophil counts) frequently during therapy.

●       Kidney function tests (serum creatinine or creatinine clearance) regularly.

●       Ophthalmologic follow-up examinations in patients being treated for CMV retinitis.

●       Monitoring for signs of infection given the bone marrow suppression risk.

Ganciclovir (the intravenous parent drug), Foscarnet, Cidofovir, Letermovir (used specifically for CMV prevention in certain transplant settings).

Generally used as a standalone antiviral for CMV management; used alongside standard immunosuppressive and antimicrobial prophylaxis regimens in transplant patients, with monitoring for added bone marrow suppression.

●       Cytomegalovirus (CMV) Medicines

●       Antiviral Therapies

●       Transplant Supportive Care

1. Top 4 Complementary Therapies For HIV

2. The Connection Between HIV and Cancer

3. HIV Medicines That Work: A Practical Guide

4. World AIDS Vaccine Day

5. The Connection Between HIV and Cancer

1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022257s009,021304s014lbl.pdf

2. https://www.drugs.com/dosage/valganciclovir.html

The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.